Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleGASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL

Evaluation of Second Generation Amiloride Analogs as Therapy for Cystic Fibrosis Lung Disease

Andrew J. Hirsh, Juan R. Sabater, Andra Zamurs, Rick T. Smith, Anthony M. Paradiso, Sam Hopkins, William M. Abraham and Richard C. Boucher
Journal of Pharmacology and Experimental Therapeutics December 2004, 311 (3) 929-938; DOI: https://doi.org/10.1124/jpet.104.071886
Andrew J. Hirsh
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Juan R. Sabater
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andra Zamurs
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rick T. Smith
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anthony M. Paradiso
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sam Hopkins
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William M. Abraham
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard C. Boucher
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Epithelial sodium channel (ENaC) blockers have been proposed as a therapy to restore mucus clearance (MC) in cystic fibrosis (CF) airways. The therapeutic effects of the first generation ENaC blocker, amiloride, in CF patients, however, were minimal. Because the failure of amiloride reflected both its low potency and short duration of action on airway surfaces, we investigated whether the increased potency of benzamil and phenamil would produce more favorable pharmacodynamic properties. In vitro potency, maximal efficacy, rate of recovery from maximal block of ENaC, and rate of drug absorption were compared for amiloride, benzamil, and phenamil in cultured human and ovine bronchial epithelial cells. In both human and ovine bronchial epithelia, the rank order of potency was benzamil > phenamil » amiloride, the maximal efficacy was benzamil = phenamil = amiloride, the recovery to baseline sodium transport was phenamil < benzamil « amiloride, and the rate of drug absorption was phenamil > benzamil » amiloride. Based on greater potency, benzamil was compared with amiloride in in vivo pharmacodynamic studies in sheep, including tracheal mucus velocity (TMV) and MC. Benzamil enhanced MC and TMV, but acute potency or duration of effect did not exceed that of amiloride. In conclusion, our data support the hypothesis that ENaC blocker aerosol therapy increases MC. However, rapid absorption of benzamil from the mucosal surface offset its greater potency, making it equieffective with amiloride in vivo. More potent, less absorbable, third generation ENaC blockers will be required for an effective aerosol CF pharmacotherapy.

Footnotes

  • A.J.H. was a recipient of a Canadian Institute of Health and Research fellowship during the period of this study. This study was supported in part by a Pilot and Feasibility Grant from the Cystic Fibrosis Foundation and the Canadian Institute of Health and Research (to A.J.H.) and by Grant 34322 from the National Institutes of Health (National Heart, Lung, and Blood Institute) (to R.C.B.). A portion of this work was presented in abstract form: Hirsh AJ and Boucher RC (2000) Absorption of Na+ channel inhibitors by cystic fibrosis airway epithelium. Pediatr Pulmonol (Suppl 20):267.

  • doi:10.1124/jpet.104.071886.

  • ABBREVIATIONS: MC, mucus clearance; ASL, airway surface liquid; CF, cystic fibrosis; ENaC, epithelial sodium channel(s); HBE, human bronchial epithelial; OBE, ovine bronchial epithelial; TMV, tracheal mucous velocity; ALI, air-liquid interface; Rt, transepithelial resistance; KRB, Krebs-Ringer bicarbonate; Isc, short-circuit current; Pcoeff, permeability coefficient(s); ETT, endotracheal tube; ANOVA, analysis of variance.

    • Received May 28, 2004.
    • Accepted July 22, 2004.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 311 (3)
Journal of Pharmacology and Experimental Therapeutics
Vol. 311, Issue 3
1 Dec 2004
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Evaluation of Second Generation Amiloride Analogs as Therapy for Cystic Fibrosis Lung Disease
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleGASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL

Evaluation of Second Generation Amiloride Analogs as Therapy for Cystic Fibrosis Lung Disease

Andrew J. Hirsh, Juan R. Sabater, Andra Zamurs, Rick T. Smith, Anthony M. Paradiso, Sam Hopkins, William M. Abraham and Richard C. Boucher
Journal of Pharmacology and Experimental Therapeutics December 1, 2004, 311 (3) 929-938; DOI: https://doi.org/10.1124/jpet.104.071886

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleGASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL

Evaluation of Second Generation Amiloride Analogs as Therapy for Cystic Fibrosis Lung Disease

Andrew J. Hirsh, Juan R. Sabater, Andra Zamurs, Rick T. Smith, Anthony M. Paradiso, Sam Hopkins, William M. Abraham and Richard C. Boucher
Journal of Pharmacology and Experimental Therapeutics December 1, 2004, 311 (3) 929-938; DOI: https://doi.org/10.1124/jpet.104.071886
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Renal Pharmacology of 8-Aminopurines
  • Mirabegron Effects in Human Detrusor Tissues
  • Resveratrol Attenuates HFD-Induced Hepatic Lipotoxicity
Show more Gastrointestinal, Hepatic, Pulmonary, and Renal

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics